Bifunctional recombinant proteins in cancer therapy: Cell penetrating peptide aptamers as inhibitors of growth factor signaling

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 12, 2003, Pages 669-675

  Buerger, Claudia ^a   Groner, Bernd ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Cancer therapy; Peptide aptamer; Protein transduction

Indexed keywords

APTAMER; EPIDERMAL GROWTH FACTOR RECEPTOR; PEPTIDE DERIVATIVE; STAT PROTEIN; THIOREDOXIN;

AMINO ACID SEQUENCE; CANCER GROWTH; CANCER INHIBITION; CANCER RESEARCH; HUMAN; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; GROWTH SUBSTANCES; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE BIOSYNTHESIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 0347478160     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0489-8     Document Type: Review

References (54)

1. Abedi MR, Caponigro G, Kamb A (1998) Green fluorescent protein as a scaffold for intracellular presentation of peptides. Nucleic Acids Res 26:623-630
2. Abu-Amer Y, Dowdy SF, Ross FP, Clohisy JC, Teitelbaum SL (2001) Tat fusion proteins containing tyrosine 42-deleted ikappa balpha arrest osteoclastogenesis. J Biol Chem 276:30499-30503
3. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B, Wels W (2000) Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 86:269-275
4. Beerli RR, Wels W, Hynes NE (1994) Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 269:23931-23936
5. Berezov A, Chen J, Liu Q, Zhang HT, Greene MI, Murali R (2002) Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem 277:28330-28339
6. Blaskovich MA, Sun A, Cantor J, Turkson R, Jove, Sebti SM (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63:1270-1279
7. Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, Hoppe-Seyler F, Groner B (2003) Sequence specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with STAT3 activation and inhibit the growth of tumor cells. J Biol Chem (in press)
8. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F (2000) Induction of apoptosis in human papilloma virus positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein [In Process Citation]. Proc Natl Acad Sci USA 97:6693-6697
9. Butz K, Denk C, Fitscher B, Crnkovic-Mertens I, Ullmann A, Schroder CH, Hoppe-Seyler F (2001) Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20:6579-6586
10. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J (2002) In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22:5423-5431
11. Cheng X, Boyer JL, Juliano RL (1997) Selection of peptides that functionally replace a zinc finger in the Spl transcription factor by using a yeast combinatorial library. Proc Natl Acad Sci USA 94:14120-14125
12. Cohen BA, Colas P, Brent R (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc Natl Acad Sci USA 95:14272-14277
13. Colas P (2000) Combinatorial protein reagents to manipulate protein function. Curr Opin Chem Biol 4:54-59
14. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin- dependent kinase 2. Nature 380:548-550
15. Colas P, Cohen B, Ferrigno PK, Silver PA, Brent R (2000) Targeted modification and transportation of cellular proteins. Proc Natl Acad Sci USA 97:13720-13725
16. Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296-313
17. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A (1996) Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271:18188-18193
18. Elliott G, O'Hare P (1997) Intercellular trafficking and protein delivery by a herpes virus structural protein. Cell 88:223-233
19. Fabbrizio E, Le Cam L, Polanowska J, Kaczorek M, Lamb N, Brent R, Sardet C (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene 18:4357-4363
20. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J (1994) Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91:664-668
21. Filipovich AH, Vallera DA, Youle RJ, Quinones RR, Neville DM Jr, Kersey JH (1984) Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease. Lancet 1:469-472
22. Ford KG, Suoberbielle BE, Darling D, Farzaneh F (2001) Protein transduction: an alternative to genetic intervention? Gene Ther 8:1-4
23. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193
24. Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55:1179-1188
25. Hoppe-Seyler F, Butz K (2000) Peptide aptamers: powerful new tools for molecular medicine. J Mol Med 78:426-430
26. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 88:1864-1868
27. Kau TR, Silver PA (2003) Nuclear transport as a target for cell growth. Drug Discov Today 8:78-85
28. Klevenz B, Butz K, Hoppe-Seyler F (2002) Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding Cell Mol Life Sci 59:1993-1998
29. Langer R (1998) Drug delivery and targeting. Nature 392 [Suppl 6679]:5-10
30. Liem AA, Chamberlain MP, Wolf CR, Thompson AM (2002) The role of signal transduction in cancer treatment and drug resistance. Eur J Surgical Oncol 28:679-684
31. Levy DE, Darnell JE (2002) Stats: transcriptional control and biological impact. Nat Rev Cell Biol 3:651-662
32. Mai JC, Mi Z, Kim SH, Ng B, Robbins PD (2001) A proapoptotic peptide for the treatment of solid tumors. Cancer Res 61:7709-7712
33. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD (2002) Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem 277:30208-30218
34. McConnell SJ, Hoess RH (1995) Tendamistat as a scaffold for conformationally constrained phage peptide libraries. J Mol Biol 250:460-470
35. Myklebust AT, Godal A, Juell S, Pharo A, Fodstad O (1994) Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 54:209-214
36. Nagahara H et al (1998) Transduction of full length TAT fusion proteins into mammalian cells: TAT-p27 kip1 induces cell migration. Nature Med 4:1449-1452
37. Norman TC, Smith DL, Sorger PK, Drees BL, O'Rourke SM, Hughes TR, Roberts CJ, Friend SH, Fields S, Murray AW (1999) Genetic selection of peptide inhibitors of biological pathways. Science 285:591-595
38. Prochiantz A (2000) Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell Biol 12:400-406
39. Ren Z, Cabell LA, Schaefer TS, McMurray JS (2003) Identification of a high affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett 13:633-636
40. Rouselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J (2000) New advances in the transport of doxorubicin through the blood brain barrier by a peptide vector mediated strategy. Mol Pharmacol 57:679-686
41. Schmidt M, Maurer-Gebhard M, Groner B, Kohler G, Brochmann-Santos G, Wels W (1999) Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 18:1711-1721
42. Schmidt S, Diriong S, Mery J, Fabbrizio E, Debant A (2002) Identification of the first Rho-GEF inhibitor, TRIPalpha, which targets the RhoA-specific GEF domain of Trio. FEBS Lett 523:35-42
43. Schwarze SR, Dowdy SF (2000) In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 21:45-48
44. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse [see comments]. Science 285:1569-1572
45. Traxler P (2003) Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opinion Ther Targets 7:215-234
46. Tyagi M, Rusnati M, Presta M, Giacca M (2001) Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276:3254-3261
47. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O (2002) Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22:3316-3326
48. Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PC, Neville DM Jr, Youle RJ (1983) Anti-T cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222:512-515
49. Vallera DA, Youle RJ, Neville DM Jr, Soderling CC, Kersey JH (1983) Monoclonal antibody toxin conjugates for experimental graft-versus-host disease prophylaxis. Reagents selectively reactive with T cells and not murine stem cells. Transplantation 36:73-80
50. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52:6310-6317
51. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, JB Rothbard (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 97:13003-13008
52. Xu CW, Luo Z (2002) Inactivation of Ras function by allele-specific peptide aptamers. Oncogene 21:5753-5757
53. Yarden Y, MX Sliwkowski (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
54. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SB, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 96:2071-2076